[Source: Science Daily]
Psychiatrists have tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms from the start of therapy after eight weeks of dosing. Positive results included increased speech fluency, faster reading completion, and shortened duration of stuttering events.
“Ecopipam was well tolerated by the study participants,” said Dr. Gerald Maguire, chair of psychiatry and neuroscience in the UCR School of Medicine, who led the study published this month in the Annals of Clinical Psychiatry. “They showed no serious adverse effects, no patient stopped treatment due to adverse events, and there were no signals of weight gain or abnormal movement disorders, events that may accompany other medications used to treat stuttering.”